Sun Pharmaceutical Industries Ltd Share Price
(SUNPHARMA)
₹1787.4
as on 04:01PM, 25 Apr 2025
Sun Pharma Performance
Day's Low
Day's High
₹1,764.2Day's Price Range₹1,815.552 Week's Low
52 Week's High
₹1,377.252-Week Price Range₹1,960.35
| Returns % | |
| 1 Month Return | + 1.62 % |
| 3 Month Return | + 0.03 % |
| 1 Year Return | + 18.64 % |
| Market Stats | |
| Previous Close | ₹1,803.90 |
| Open | ₹1,806.00 |
| Volume | 20.37L |
| Upper Circuit | ₹1,984.20 |
| Lower Circuit | ₹1,623.60 |
| Market Cap | ₹4,28,857.13Cr |
Sun Pharma Fundamentals
P/E Ratio
37.47
PEG Ratio
3.54
Market Cap
₹4,28,857.13 Cr
P/B Ratio
16.41
EPS
40.21
Dividend Yield
0.83
Sector
Pharmaceuticals
ROE
12.05
Mutual Fund Holdings of Sun Pharma
Sun Pharma Analyst Rating
based on 37 analysts
81.08%
Buy
10.81%
Hold
8.11%
Sell
Based on 37 analysts offering long term price targets for Sun Pharma. An average target of ₹2047.89
Source: S&P Global Market Intelligence
Sun Pharma Share analysis
Sun Pharma price forecast by 37 analysts
Upside of14.57%
High
₹2450
Target
₹2047.89
Low
₹1500
Sun Pharma target price ₹2047.89, a slight upside of 14.57% compared to current price of ₹1787.4. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharma revenue growth forecast
Expected growth rate Q1, FY2027:32.23%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharma EPS growth forecast
EPS estimate Q1, FY2027:56.55%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Sun Pharmaceutical Industries Ltd
Sun Pharma Reports Positive Osteoarthritis Drug Trial Results - 24 Apr, 2025
Sun Pharmaceutical Industries and Moebius Medical announced positive results for MM-II, a novel osteoarthritis treatment, showing significant pain relief and a favorable safety profile. This development may provide a promising alternative to existing treatments.Sun Pharma Anticipates Strong US Market Growth - 23 Apr, 2025
Sun Pharmaceutical Industries is projected to deliver a 12% year-over-year growth in the US market, primarily due to the success of its specialty portfolio.Sun Pharma Shares Rise with Buy Recommendation - 20 Apr, 2025
Sun Pharmaceutical Industries Ltd shares closed at Rs.1,757.00, up 3.77%. Emkay Global recommends a Buy with a target price of Rs.2,400, suggesting a 40% upside.Sun Pharma Faces Recall Amid Regulatory Challenges - 14 Apr, 2025
Sun Pharmaceutical Industries is recalling several medicines from the US market due to manufacturing-related problems, contributing to a challenging environment for the company amid strong competition and regulatory pressures.Sun Pharma Faces Recall Amid Stock Recovery - 13 Apr, 2025
Sun Pharmaceutical Industries has seen a recovery in its stock, regaining nearly half of its earlier losses. However, it is also recalling 13,700 bottles of Gabapentin capsules due to cross-contamination concerns, which may impact investor sentiment.Sun Pharma Gains Court Approval for Leqselvi Launch - 10 Apr, 2025
Sun Pharmaceutical Industries received a favorable ruling from the U.S. Court of Appeals, lifting the injunction on Leqselvi's launch, projected to boost sales significantly in FY26 and FY27.Sun Pharma Faces Challenges from US Tariff Announcement - 09 Apr, 2025
Sun Pharmaceutical Industries Ltd is expected to face challenges due to upcoming US tariffs on pharmaceutical imports, leading to a negative trading outlook and lower stock performance.Sun Pharma Launches New Drug Amid Market Challenges - 07 Apr, 2025
Sun Pharmaceutical Industries launched FEXUCLUE for Erosive Esophagitis, demonstrating high efficacy in trials. However, shares fell 3.47% as the Nifty Pharma index hit a 10-month low.Sun Pharma Faces Tariff Concerns Amid Growth Prospects - 04 Apr, 2025
Sun Pharma shares declined due to tariff concerns after Trump's announcement, but the company is projected to achieve significant sales growth in Q4FY25, maintaining a positive outlook from analysts.Sun Pharma Shares Surge on Tariff Exemption News - 03 Apr, 2025
On April 3, 2025, Sun Pharmaceutical Industries saw its shares rise over 5% after the U.S. confirmed that Indian pharmaceutical exports would not face new tariffs. This decision is viewed positively by brokerages, highlighting Sun Pharma's resilience amid potential tariff disruptions.Sun Pharma Reports Strong Growth Amid Challenges - 02 Apr, 2025
Sun Pharmaceutical Industries Ltd reported a 10.4% revenue growth in FY24, driven by specialty drugs and a robust Indian market, despite potential tariff pressures on exports.Concerns Over Tariffs Impacting Pharma Sector - 30 Mar, 2025
India's 10% tariff on US pharma imports raises concerns among industry groups, highlighting potential cost burdens for distributors and generic manufacturers amid minimal US duties.Sun Pharma Enters Merger Agreement with Checkpoint Therapeutics - 29 Mar, 2025
Sun Pharmaceutical Industries Ltd has entered into a merger agreement with Checkpoint Therapeutics, Inc. This merger aims to facilitate the launch of UNLOXCYT in the U.S. and support marketing authorization in Europe, enhancing the company's strategic position in the oncology market.Sun Pharma Faces Challenges Amid Market Decline - 27 Mar, 2025
Sun Pharmaceutical Industries Ltd is impacted by Lyndra Therapeutics ceasing operations due to funding issues and a broader decline in Indian pharma stocks amid tariff concerns.
Insights on Sun Pharmaceutical Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 12.11% to 12.24% in Dec 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, SUNPHARMA stock has moved up by 2.4%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 12.58K Cr → 14.14K Cr (in ₹), with an average increase of 3.8% per quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 8.89% to 8.92% in Dec 2024 quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 18.02% to 18.05% in Dec 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 49.7% return, outperforming this stock by 31.1%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 136.8% return, outperforming this stock by 42.1%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 3.04K Cr → 2.90K Cr (in ₹), with an average decrease of 4.5% per quarter
Sun Pharma News
Top Gainers and Losers in Indian Markets on April 25
ACC plunged over 6% after its Q4 earnings missed Street expectations, reflecting tepid demand recovery in the cement sector. Margin pressures due to rising fuel and raw material costs added to the negative surprise. The stock remained under selling pressure as analysts trimmed earnings estimates post results.25 Apr, 2025 04:32 PMQ4 Results impact: ACC, Cyient shares tumble 6% amid tepid March quarter earnings
The Adani Group firm on April 24 reported a consolidated net profit of Rs 751 crore for Q4 FY25. This marked a fall of nearly 20 percent from the Rs 943 crore net profit reported in Q4 FY24. The firms consolidated revenue however rose 13 percent year-on-year to Rs 5,992 crore in Q4FY25 as against Rs 5,317 crore in Q4FY24. The cement company also declared dividend of Rs 7.5 per share for FY25. June 13 has been fixed as the record date for the dividend and it shall be paid before July 1. The shares of the company have now recorded their worst fall in 2025 so far. Axis Capital has cut the rating of ACC shares to Reduce from Add, with a target price of Rs 2,050 apiece. The latest target price, however, implies an upside potential of nearly 6 percent from the current market price.25 Apr, 2025 02:13 PMACC Faces Major Loss After Q4 Results Decline
Shares of Adani Group-owned cement manufacturer tumbled over 6 per cent on Friday after its profit for the fourth quarter of the financial year 2025 (Q4 FY25) declined 20.4 per cent year-on-year (Y-o-Y). ACC's stock fell as much as 6.5 per cent during the day to ₹1,931 per share, the worst intraday loss since November 21 this year, according to Bloomberg data. The stock trimmed losses to trade 5 per cent lower at ₹1,961 apiece, compared to a 1.38 per cent decline in Nifty50 as of 12:11 PM. The company's net profit for the fourth quarter declined 20.4 per cent Y-o-Y to ₹7,51.03 crore. The Adani-owned company's revenue from operations grew 12.7 per cent to ₹5,991.67 crore amid higher trade sales volume and share of premium products in trade sales. Revenue growth surpassed Bloomberg analysts estimate of ₹5,904 crore. The company's total expenses in Q4 FY25 stood at ₹5,514.82 crore, up 13.11 per cent Y-o-Y. Earnings before interest, taxes, depreciation, and amortisation (Ebitda) stood at ₹830 crore, down 0.84 per cent. Ebitda margin declined to 13.7 per cent in Q4 FY25 from 15.5 per cent the year before. Additionally, ACC announced a dividend on equity shares at ₹7.50 per share.25 Apr, 2025 12:36 PMSun Pharma Financials
Sun Pharma Index Inclusions
Sun Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 18.05% | 0.17 | |
| Mutual Funds | 12.24% | 1.02 | |
| Retail Investors | 8.92% | 0.33 | |
| Others | 6.31% |
Sun Pharma Key Indicators
Sun Pharma Valuation
Sun Pharma in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (37.47x)
April 25, 2025
Industry (55.10x)
April 25, 2025
Highest (184.63x)
August 28, 2020
Sun Pharma Earnings and Dividends
Sun Pharmaceutical Industries Ltd Earnings Results
Sun Pharmaceutical Industries Ltd’s net profit jumped 15.04% since last year same period to ₹2,903.38Cr in the Q3 2024-2025. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated -4.5% fall in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceutical Industries Ltd Dividends January,2025
In the quarter ending December 2024, Sun Pharmaceutical Industries Ltd has declared dividend of ₹10.50 - translating a dividend yield of 1.34%.
Read More about Dividends
Sun Pharma Technicals Summary
Bearish
Neutral
Bullish
Sun Pharmaceutical Industries Ltd is currently in a Bullish trading position according to technical analysis indicators.
Sun Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,28,857.13 Cr | 52.97% | 0.68 | ₹9,648 Cr | ₹48,496 Cr | |
| HOLD | ₹1,59,612.98 Cr | 29.57% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,09,614.17 Cr | 31.63% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹37,440.71 Cr | -2.83% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹23,855.08 Cr | -4.09% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Sun Pharma
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Revenue: ₹13,436.94Cr as on December 2024 (Q4 24)
Net Profit: ₹2,917.54Cr as on December 2024 (Q4 24)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharma |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Sun Pharmaceutical Industries Ltd
What is Sun Pharmaceutical Industries Ltd price today?
Sun Pharmaceutical Industries Ltd share price today stands at ₹1787.4, Open: ₹1806, Previous Close: ₹1803.9, High: ₹1815.5, Low: ₹1764.2, 52 Week High: ₹1960.35, 52 Week Low: ₹1377.2.
How to Buy Sun Pharmaceutical Industries Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Sun Pharmaceutical Industries Ltd shares
What are today's traded volumes of Sun Pharmaceutical Industries Ltd?
Today's traded volume of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is 20.37L.
What is today's market capitalisation of Sun Pharmaceutical Industries Ltd?
Today's market capitalisation of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is ₹428857.13Cr.
What is the 52 Week High and Low Range of Sun Pharmaceutical Industries Ltd?
How much percentage Sun Pharmaceutical Industries Ltd is down from its 52 Week High?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1787.4. It is down -8.82% from its 52 Week High price of ₹1960.35
How much percentage Sun Pharmaceutical Industries Ltd is up from its 52 Week low?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1787.4. It is up 29.79% from its 52 Week Low price of ₹1377.2